Myovant Sciences Ltd (NYSE:MYOV) has been given a consensus rating of “Buy” by the seven ratings firms that are covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $30.25.
A number of equities research analysts have issued reports on MYOV shares. Zacks Investment Research raised shares of Myovant Sciences from a “sell” rating to a “hold” rating in a research note on Wednesday, October 10th. JPMorgan Chase & Co. started coverage on shares of Myovant Sciences in a research note on Thursday, September 13th. They set an “overweight” rating and a $39.00 target price for the company.
In related news, Director Mark Altmeyer bought 3,500 shares of the firm’s stock in a transaction on Saturday, November 17th. The stock was bought at an average price of $13.38 per share, with a total value of $46,830.00. Following the purchase, the director now directly owns 3,500 shares of the company’s stock, valued at approximately $46,830. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 3.10% of the company’s stock.
Several large investors have recently modified their holdings of MYOV. Atria Investments LLC acquired a new stake in shares of Myovant Sciences in the 3rd quarter valued at $201,000. Renaissance Technologies LLC acquired a new stake in shares of Myovant Sciences in the 2nd quarter valued at $297,000. Matisse Capital acquired a new stake in shares of Myovant Sciences in the 2nd quarter valued at $349,000. Millennium Management LLC lifted its stake in shares of Myovant Sciences by 54.3% in the 1st quarter. Millennium Management LLC now owns 106,868 shares of the company’s stock valued at $2,273,000 after purchasing an additional 37,602 shares during the last quarter. Finally, JPMorgan Chase & Co. lifted its stake in shares of Myovant Sciences by 6.2% in the 1st quarter. JPMorgan Chase & Co. now owns 106,944 shares of the company’s stock valued at $2,275,000 after purchasing an additional 6,263 shares during the last quarter. 21.04% of the stock is owned by institutional investors.
NYSE MYOV traded down $1.50 on Monday, hitting $19.51. 3,556 shares of the stock were exchanged, compared to its average volume of 37,054. Myovant Sciences has a 52-week low of $11.30 and a 52-week high of $27.45. The company has a debt-to-equity ratio of 0.73, a quick ratio of 3.07 and a current ratio of 3.07. The stock has a market cap of $1.43 billion, a price-to-earnings ratio of -8.03 and a beta of -2.00.
Myovant Sciences (NYSE:MYOV) last posted its quarterly earnings data on Tuesday, August 7th. The company reported ($0.98) earnings per share for the quarter, missing the consensus estimate of ($0.90) by ($0.08). On average, research analysts forecast that Myovant Sciences will post -3.91 EPS for the current fiscal year.
Myovant Sciences Company Profile
Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer.
Further Reading: Why do earnings reports matter?
Receive News & Ratings for Myovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.